BioSpace News Archive

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00per share, before underwriting discounts.

Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer’s disease (“AD”), today announced the authorization of an inducement grant to newly-appointed Chief Operating Officer and General Counsel, Michael Ciraolo, J.D., Ph.D.

Diem Labs has committed $20,000 to Vitamin Angels this year and in honor of the charity’s 25th anniversary will include as part of that donation 25 cents for each product sale

Partners for Quality, Inc. is providing notice of a recent incident involving potential unauthorized access to personal information.

Maxinovel Pharmaceuticals, Inc. presented in the 2019 AACR the head to head comparison of its orally active small molecule PD-L1 inhibitor with commercially marketed PD-L1 antibody drug Durvalumab in the human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice model [LB-018].

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 21, 2019 to file lead plaintiff applications in a securities class action lawsuit against Healthcare Services Group, Inc., if they purchased the Company’s securities between April 11, 2017 and March 4, 2019, inclusive (the “Class Period”).

The U.S. Food and Drug Administration permitted marketing of the first medical device to treat attention deficit hyperactivity disorder.

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker data for its investigational drug, mavacamten.

Young Living Essential Oils, the world leader in essential oils, announced the promotion of Sarah Bjorgaard as General Manager, U.S. Market

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock